SCHEMBL90116

SCHEMBL90116

COCCCOc1cc(CO)cc(OC)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
MAPT P10636 4/20 0.38
HPGD P15428 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PRSS1 P07477 2/20 0.36
MAPK1 P28482 2/20 0.36
LMNA P02545 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
REN P00797 1/20 0.36
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL88770 0.85 PTGS2 (0.48) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL89710 0.85 L3MBTL1 (0.39) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL3394143 0.84 MEN1 (0.46) ALOX15TSHRHSD17B10MEN1KMT2A
SCHEMBL1911337 0.83 SPIN1 (0.41) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL18508692 0.81 MAPT (0.33) ALOX15TSHRHSD17B10MEN1KMT2A
SCHEMBL2810242 0.80 REN (0.48) MAPTHPGDL3MBTL1NPC1RAB9A
SCHEMBL29521379 0.80 REN (0.48) MAPTHPGDL3MBTL1NPC1RAB9A
SCHEMBL3080203 0.77 TSHR (0.44) TSHRMEN1KMT2AMAPTHPGD
SCHEMBL6042539 0.76 SMN1; SMN2 (0.42) HSD17B10MEN1KMT2AMAPTHPGD
SCHEMBL89209 0.75 ALDH1A1 (0.51) TSHRMEN1KMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 ALOX15 973/4885TSHR 1095/4885HSD17B10 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.